Clinical Trials Logo

Amyotrophic Lateral Sclerosis clinical trials

View clinical trials related to Amyotrophic Lateral Sclerosis.

Filter by:

NCT ID: NCT04997954 Active, not recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

EMERALD TRIAL Open Label Extension Study

EMERALD-OLE
Start date: May 17, 2021
Phase: Phase 4
Study type: Interventional

EMERALD OLE trial is an open-label extension of the EMERALD trial. Long term tolerability and safety of the MediCabilis CBD oil has not been extensively studied. EMERALD OLE aims to establish data on the prolonged used of the study drug product. All participants who completed the EMERALD trial will be offered to enter EMERALD OLE. Participants will be taking the active drug MediCabilis CBD oil for 6 months.

NCT ID: NCT04993755 Active, not recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

Start date: October 1, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2a study to assess the the safety and tolerability of TPN-101 in patients with Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) Associated with Hexanucleotide Repeat Expansion in the C9orf72 gene (C9ORF72 ALS/FTD).

NCT ID: NCT04961450 Enrolling by invitation - Clinical trials for Amyotrophic Lateral Sclerosis

Explore Biomarkers of Motor Neuron Disease/Frontal Dementia Spectrum Disease in China

Start date: June 24, 2021
Phase:
Study type: Observational

1. To investigate the biomarkers of MND/FTD spectrum disease 2. To explore the possible pathogenesis of MND/FTD

NCT ID: NCT04960540 Active, not recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

Multimodal Brain Imaging Study

Start date: August 1, 2019
Phase:
Study type: Observational

To explain the key brain network nodes and their brain mechanisms of ALS language cognitive impairment and decline, reveal the neural mechanism of the association between ALS language cognitive impairment and motor executive function, and provide potential early diagnostic markers and targeted therapeutic targets for ALS language cognitive impairment.

NCT ID: NCT04956822 Recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

Application of Motor Unit Estimation Index in Amyotrophic Lateral Sclerosis and Related Diseases

Start date: June 1, 2018
Phase:
Study type: Observational

This was a cross-sectional study in which patients were divided into 20 patients with amyotrophic lateral sclerosis, 20 patients with peroneal muscular dystrophy, 20 patients with Kennedy's disease and 30 healthy controls, in which patients with amyotrophic lateral sclerosis continued to be followed up for 1 year and the results of 4 cross-sectional examinations were taken.

NCT ID: NCT04953624 Recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

Appetite and Related Factors in Patients With ALS

Start date: August 1, 2020
Phase:
Study type: Observational

Chinese cnaq scale was used to evaluate the appetite changes of Chinese ALS patients; Objective to investigate the related factors of appetite changes in ALS patients; Objective to investigate the effect of anorexia on the progression and survival of ALS patients.

NCT ID: NCT04953494 Not yet recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

Pleiotropy and Mechanism of Peripheral Nerve Related Genes in the Progression of Amyotrophic Lateral Sclerosis

Start date: August 1, 2021
Phase:
Study type: Observational

This study will establish a comprehensive exon database of ALS patients, lay the foundation for screening the genes related to the occurrence and development of the disease, support the theory of ALS disease progression from peripheral to central, and reveal the correlation between the functional level of peripheral nerve and the prognosis of the disease at the gene level for the first time, and provide the basis for the mechanism research at the molecular level.

NCT ID: NCT04953481 Recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

Home Care Needs and Current Nursing Status of Patients With Amyotrophic Lateral Sclerosis

Start date: January 1, 2021
Phase:
Study type: Observational

The purpose of this study is to comprehensively investigate and analyze the home care needs and status quo of ALS patients in China, and to clarify their home care needs and status quo, so as to provide reference for the development of home care service planning and policy measures for ALS patients.

NCT ID: NCT04953286 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

Ocular Surface Metabolo-lipidomics in Lateral Amyotrophic Sclerosis

LARMOMIQUE
Start date: September 17, 2021
Phase: N/A
Study type: Interventional

Amyotrophic Lateral Sclerosis (ALS) is the most common neurodegenerative disease affecting the motor neuron. Currently, there is no diagnostic test and no examination that can predict the evolution of this pathology. The search for diagnostic and prognostic biomarkers is therefore essential for a better understanding of the pathophysiology of ALS, which remains poorly understood, and also for better clinical management. The ocular surface, made up of liquid elements, tears, and cells, is an accessible anatomical-physiological entity that has demonstrated its usefulness in the identification of biomarkers in neurodegenerative diseases such as Parkinson's or Alzheimer's. To date, no study has explored the ocular surface as a biomarker in ALS

NCT ID: NCT04952155 Recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

Low Dose IL-2 in the Treatment of Immune-associated ALS Syndrome

Start date: January 1, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study was to evaluate the efficacy and safety of low-dose IL-2 in the treatment of immunorelated ALS syndrome.